期刊文献+

HBV与LDH对弥漫性大B细胞淋巴瘤患者化学治疗效果的影响——附144例报告 被引量:4

Effect of HBV / LDH on clinical efficacy of chemotherapy in treatment of diffuse large B cell lymphoma:report of 144 cases
下载PDF
导出
摘要 目的探讨HBV与乳酸脱氢酶(LDH)对弥漫性大B细胞淋巴瘤(DLBCL)患者化学治疗效果的影响。方法以144例初治DLBCL患者为研究对象,其中HBsAg(+)66例,LDHdt(LDH水平正常为N、高于正常为H)77例。将其分别按血清HBsAg是否(+)、LDH水平是否正常分为4组:HBsAg(-)/LDH-N组45例,HBsAg(-)/LDH-H组33例,HBsAg(+)/LDH-N组22例,HBsAg(+)/LDH-H组44例。所有患者采用CHOP方案治疗4~6个疗程,分析HBV、LDH对化学治疗总有效率的影响。结果 HBsAg(+)者化学治疗总有效率为62.1%(41/66);HBsAg(-)者化学治疗总有效率为82.1%(64/78),HBsAg(-)者总有效率高于HBsAg(+)者(P〈0.01)。LDH-H者化学治疗总有效率为64.9%(50/77);LDH-N者化学治疗总有效率为82.1%(55/67),LDH-N者总有效率高于LDH-H者(P〈0.05)。分组结果显示:①HBsAg(-)/LDH-N组治疗总有效率为84.4%(38/45);②HBsAg(-)/LDH-H组治疗总有效率为78.8%(26/33);③HBsAg(+)/LDH-N组治疗总有效率为77.3%(17/22);④HBsAg(+)/LDHdt组治疗总有效率为54.5%(24/44),4组总有效率比较差异有统计学意义(P=0.01)。4组总有效率的两两比较结果显示HBsAg(-)/LDH-N组总有效率高于HBsAg(+)/LDH-H组(P=0.002),其余各组的两两比较结果尚未有统计学意义。结论感染HBV与高LDH可能对DLBCL的化学治疗效果有负面影响.两者可能起协同作用。 Objective To evaluate the effect of hepatitis B virus(HBV) and lactate dehydrogenase(LDH) upon the clinical efficacy- of chemotherapy in the treatment of diffuse large B cell lymphoma(DLBCL).Methods In total,144 patients with DLBCL who were treated for the first time were recruited in this study.Among them,66 cases were found to be HBsAg(+) and 77 with high level of LDH(LDH-H).According to HBsAg status(positive/negative) and LDH level(high/nomml),all participants were divided into the HBsAg(-) /LDH-N(n=45),HBsAg(-) /LDH-H(n=33),HBsAg(+) /LDH-N(n=22) and HBsAg(+) /LDH-H groups(n = 44).All patients received 4-6 cycles of CHOP regime.The effect of HBV and LDH upon the overall efficacy of chemotherapy was assessed.Results The overall efficacious rate of chemotherapy in DLBCL patients with HBsAg(+) was 62.1%(41/66),significantly lower compared with 82.1%(64/78) of those with HBsAg(-).The overall efficacious rate of chemotherapy in DLBCL patients with LDH-H was 64.9%(50/77),considerably lower than 82.1%(55/67) of their counterparts with LDH-N(P 0.05).Group comparison revealed that overall efficacious rate of chemotherapy in the HBsAg(-) /LDHN group was 84.4%(38/45),78.8%(26/33) in the HBsAg(-) /LDH-H group,77.3%(17/22) in the HBsAg(+) /LDH-N group and 54.5%(24/44) in the HBsAg(+) /LDH-H group with statistical significance among four groups(P = 0.01).Paired comparison indicated that overall efficacious rate in the HBsAg(-) /LDH-N group was significantly higher than that in the HBsAg(+) /LDH-H group(P =0.002).No statistical significance was noted among the other groups.Conclusion hffection of HBV and high level of LDH probably exert a negative and synergetic effect upon the clinical efficacy of chemotherapy in treating DLBCL.
出处 《新医学》 2015年第12期808-811,共4页 Journal of New Medicine
基金 国家自然科学基金青年项目(81302037) 广州医科大学博士启动基金(2012C65)
关键词 弥漫性大B细胞淋巴瘤 乙型肝炎病毒 乳酸脱氢酶 Diffuse large B cell lymphoma Hepatitis B virus Lactate dehydrogenase
  • 相关文献

参考文献5

二级参考文献79

共引文献17

同被引文献53

  • 1梁晓峰,陈园生,王晓军,贺雄,陈丽娟,王骏,林长缨,白呼群,严俊,崔钢,于竞进.中国3岁以上人群乙型肝炎血清流行病学研究[J].中华流行病学杂志,2005,26(9):655-658. 被引量:967
  • 2卢兴国,丛玉隆.世界卫生组织对造血和淋巴组织肿瘤的分类和诊断标准[J].中华检验医学杂志,2006,29(6):570-573. 被引量:16
  • 3Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling[J]. Nature, 2000,403(6769) :503-511.
  • 4Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study[J]. Blood,2012,120(19) : 3986-3996.
  • 5Jacobs NL, Holtan SG, Porrata LF, et al. Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count[J]. Am J HematoI, 2010,85(3) :160-163.
  • 6Ho CL, Lu CS, Chen JH, et al. Neutrophil/lymphocyte ratio, lymphocyte/monocyte ratio, and absolute lymphocyte count/ absolute monocyte count prognostic score in diffuse large B- Cell lymphoma useful prognostic tools in the rituximab era[J]. Medicine (Baltimore) , 2016,94 (24) : e993.
  • 7Vassilakopoulos TP, Dimopoulou MN, Angelopoulou MK, et al. Prognostic implication of the absolute lymphocyte to absolute monocyte count ratio in patients with classical hodgkin lymphoma treated with doxorubicin, bleomyein, vinblastine, and daearbazine or equivalent regimens[J]. Oncologist, 2016, 21(3) :343-353.
  • 8Belotti A, Doni E, Boiis S, et aL Peripheral blood lymphocyte/ monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era[J]. Clin Lymphoma Myeloma Leuk, 2015,15 (4) :208-213.
  • 9Koh YW, Jung SJ, Yoon DH, et al. The absolute lymphocyte to monocyte ratio is associated with poor prognosis in classical Hodgkin lymphoma patients younger than 60 years of age[J]. Hematol Oncol, 2015,33(3) :133-140.
  • 10Porrata LF, In wards DJ, Ansell SM,et al. Infused autograft lymphocyte to monoeyte ratio and survival in diffuse large B cell lymphoma[J]. Biol Blood Marrow Transplant, 2014,20 (11) :1804-1812.

引证文献4

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部